Key Highlights
- Cuprina Holdings (NASDAQ:CUPR) was trading down 9.9% at USD 1.51 in pre-market on Friday, November 13, 2026, against a close of USD 1.68 on November 12, 2026.
- Published market data shows a Market Value of about USD 11.77 million, about 7.00 million shares and a trailing twelve-month net loss of about USD 3.63 million.
- The 52-week range runs from USD 1.445 to USD 14.80, so the quote sits near the bottom of its range after a 1-for-8 share consolidation in May 2026.
- On October 2, 2026 it announced a deal for seven Singapore clinics at about SGD 4.0 million, or about USD 3.1 million, with completion expected on or before November 1.
Drop Leaves the Stock Near Its 52-Week Low
Cuprina Holdings was quoted at USD 1.51 in pre-market, down 9.9%, after closing at USD 1.68 on November 12. No company release, filing or analyst action dated November 11 to November 13, 2026 explaining the move was found. The pre-market quote is the figure of record only for this session. Market data puts the 52-week low at USD 1.445, so the quote is about 4.5% above it, calculated. With roughly 7.00 million shares outstanding, a small number of trades can move the price, and quoted moves can reverse. The prior close implied by the screener is about USD 1.676, close to the USD 1.68 reported close, calculated.
Offering, Clinic Deal and the Wound-Care Business
The Singapore company sells MEDIFLY medical-grade sterile blowfly larvae for wound debridement and received FDA 510(k) clearance for MEDIFLY Maggots on June 15, 2026. A public offering closed on September 17, 2026, with the underwriter's over-allotment closing on September 29, though its size was not found. On October 2 it announced the purchase of East Coast Podiatry, with five clinics, and Orchard Clinic, with two, for about SGD 4.0 million, 75% in cash and 25% in lock-up shares priced off a 30-day average. The targets had roughly SGD 9.1 million of unaudited 2025 Revenue and about SGD 1.2 million of normalized EBITDA. Selling wound-care products to hospitals and clinics is a niche market, and the clinic purchase adds a services revenue line that the company has not had before.
Share Count, Listing History and Integration Risk
The company announced a 1-for-8 share consolidation on May 22, 2026 and regained Nasdaq compliance on June 12, 2026, after a minimum bid price notice on November 28, 2025. That history shows the stock has had trouble holding the minimum bid. Completion of the clinic purchase was not confirmed in the material found, and the unaudited figures could change. Paying cash for a purchase while losing money can strain a small balance sheet, and further issuance would dilute holders. The cash balance was not found. Investors should expect questions about how the clinics will be funded and run from a small headquarters team of about 10 employees.
Where Things Stand
The fall has no announced cause. Cuprina Holdings (NASDAQ:CUPR) was down 9.9% at USD 1.51 in pre-market, close to its 52-week low, and nothing dated November 11 to November 13 explains it. The balance of evidence points to a small, loss-making company that has raised capital, consolidated its shares and moved into clinic ownership, which leaves it exposed to dilution and integration risk. Next markers are confirmation that the clinic deal closed, third-quarter results and any listing notice. Pre-market moves on a thin share base can reverse.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...